Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313138

— · D

e52b3e8e-49ff-5997-ae72-e6b264107d88

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.590
  • ANGIOGENESIS+0.530
  • INTERFERON_GAMMA_RESPONSE+0.520
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
  • IL6_JAK_STAT3_SIGNALING+0.500
  • INFLAMMATORY_RESPONSE+0.470
  • NOTCH_SIGNALING+0.440
  • INTERFERON_ALPHA_RESPONSE+0.430
  • COMPLEMENT+0.400
  • COAGULATION+0.390

Top 10 suppressed

  • MYC_TARGETS_V2-0.470
  • DNA_REPAIR-0.320
  • E2F_TARGETS-0.250
  • ESTROGEN_RESPONSE_LATE-0.230
  • MITOTIC_SPINDLE-0.220
  • G2M_CHECKPOINT-0.190
  • ESTROGEN_RESPONSE_EARLY-0.180
  • MYC_TARGETS_V1-0.030
  • CHOLESTEROL_HOMEOSTASIS-0.020
  • UNFOLDED_PROTEIN_RESPONSE-0.020

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120060029.TNBC
breast-umap@18
—D0.878
2MBCProject_0419_T2_RNA
breast-umap@18
—A0.876
3MBCProject_0698_T1_RNA
breast-umap@18
—A0.874
4MNG867
mng-umap@100
——0.869
5TCGA-A2-A0T1-01A-21R-A084-07
breast-umap@18
—D0.860
6MBCProject_0065_T1_RNA
breast-umap@18
—C0.859
7TCGA-BH-A0B7-01A-12R-A115-07
breast-umap@18
—C0.857
8BS_RRAEQZ97
brain-umap@2
pilocytic astrocytoma—0.856
9TCGA-CN-4733-01A-02R-1873-07
head-neck@1
——0.855
10MBCProject_0734_T1A_RNA
breast-umap@18
—A0.855

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 40 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.590Idelalisib— uncovered
ANGIOGENESIS0.530Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.520Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.510Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.470Idelalisib— uncovered
NOTCH_SIGNALING0.440Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.430Inavolisib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
IL2_STAT5_SIGNALING0.370Idelalisib— uncovered
KRAS_SIGNALING_UP0.360Inavolisib— uncovered
HEDGEHOG_SIGNALING0.350Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.350Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.320Inavolisib— uncovered
APICAL_SURFACE0.270Temsirolimus— uncovered
APOPTOSIS0.270Idelalisib— uncovered
APICAL_JUNCTION0.260Inavolisib— uncovered
MYOGENESIS0.260Inavolisib— uncovered
UV_RESPONSE_DN0.250Inavolisib— uncovered